Avidity Partners Management
TENX icon

Avidity Partners Management’s Tenax Therapeutics TENX Stock Holding History

Avidity Partners Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87M Buy
265,934
+50,000
+23% +$639K 0.62% 21
2026
Q1 		$3.45M Buy
+215,934
New +$2.92M 0.7% 18

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Avidity Partners Management's TENX Position: Q2 2026 in Review

Avidity Partners Management increased its Tenax Therapeutics (TENX) stake by 23% in Q2 2026, buying an estimated $639K and bringing the position to 265,934 shares worth $3.87M. The position accounts for 0.62% of the portfolio, ranked #21.

Avidity Partners Management first reported a position in TENX in Q1 2026 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Avidity Partners Management held 265,934 shares of Tenax Therapeutics worth $3.87M as of Q2 2026.
  • Avidity Partners Management bought 50,000 Tenax Therapeutics shares in Q2 2026, an estimated $639K.
  • Tenax Therapeutics made up 0.62% of Avidity Partners Management's portfolio in Q2 2026, its #21 holding.
  • Avidity Partners Management first reported a position in Tenax Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.